Latebreakers: Low-dose estrogen gel granted approval
Upsher-Smith Laboratories will market the lowest available dose of estradiol gel for the treatment of moderate to severe vasomotor symptoms associated with menopause following the FDA approval of Divigel 0.1%.
Upsher-Smith Laboratories will market the lowest available dose of estradiol gel for the treatment of moderate to severe vasomotor symptoms associated with menopause following the FDA approval of Divigel 0.1%. The topical formulation contains 17 beta-estradiol and is quick-drying and odorless, according to the manufacturer. Divigel will be supplied in single-dose foil packets of 0.25, 0.5, and 1 gm, containing 0.25, 0.5, and 1 mg of estradiol, respectively, and should be applied daily to an area that measures five by seven inches on the thigh. In trials, both the 0.5- and 1-gm treatment groups had a statistically significant reduction in frequency and severity of vasomotor symptoms by week four and, in the 0.25-gm group, by week seven of treatment.
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
